I'm not a holder - nor do I frequent the NEU forums - but I do some work in the local pharma industry - and stumbled across this article in Pharma in Focus today (it's the local daily news mostly subscribed to by Australian phase industry folk). Figured you lot would be keen to see some coverage.
I've been watching NEU for a long while now - surely it's horrendously underpriced? Maybe it doesn't have the 'glamour' of osteoarthritis - but there does seem to be huge opportunity for this stock. The market is a strange and fickle beast.
Ann: Approval received for final stage of NNZ-2591 clinical trial, page-23
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.29 |
Change
-0.195(1.26%) |
Mkt cap ! $1.947B | |||
| Open | High | Low | Value | Volume |
| $15.20 | $15.33 | $15.02 | $5.594M | 368.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 750 | $15.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.29 | 430 | 8 |
View Market Depth
| Last trade - 15.18pm 22/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |